151447-85-7

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-(3-chlorophenyl)-3-methyl-piperazine is utilized as a key precursor or intermediate in the synthesis of a diverse range of medications. Its unique chemical structure allows for the development of new therapeutic agents with potential applications in various medical fields.
Used in Central Nervous System Research:
1-(3-CHLOROPHENYL)-3-METHYL-PIPERAZINE is employed in the study of its affinity for specific receptors within the central nervous system. Understanding these interactions can lead to the development of novel treatments for neurological and psychiatric conditions.
Used in the Treatment of Psychiatric Disorders:
1-(3-chlorophenyl)-3-methyl-piperazine is being investigated for its potential role in the treatment of psychiatric disorders. Its interaction with central nervous system receptors may offer new avenues for therapeutic intervention in conditions such as anxiety, depression, and schizophrenia.
Used in the Treatment of Neurological Diseases:
1-(3-CHLOROPHENYL)-3-METHYL-PIPERAZINE is also being explored for its potential applications in the treatment of neurological diseases. Its pharmacological properties may contribute to the development of new therapies for conditions like Alzheimer's, Parkinson's, and epilepsy.

Upstream product

• 108-42-9 3-chloro-aniline 
• 14088-83-6 N-(3-chlorophenyl)-1,2-diaminoethane 
• 220910-06-5 N-<2-(3-chlorobenzamino)ethyl>alanine ethyl ester 
• 151447-78-8 1-(3-chlorophenyl)-3-methylpiperazin-2-one 

Downstream Products

• 151447-91-5 4-(3-chlorophenyl)-1-(3-chloropropyl)-2-methylpiperazine 

Relevant academic research and scientific papers

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

PHARMACEUTICAL COMPOSITION COMPRISING A 1-(3-CHLOROPHENYL)-3-ALKYLPIPERAZINE FOR TREATING APETITE DISORDER

Use of a 1- (3-chlorophenyl) -3-alkylpiperazine of formula (I), in racemic (R, S) form or in the form of the (S) enantiomer, in which R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, for treating apetite disorder. A pharmaceutical composition that comprises a therapeutically effective amount of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I) as previously defined or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, and at least one pharmaceutically acceptable excipient.

Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT(2A) and α1 receptor binding affinity

A series of triazolopyridine derivatives (compounds 2a-1) were synthesized in order to explore the effect of modifications of the alkylpiperazine moiety of trazodone (fragment A) on binding affinity for 5HT(2A) and α1 receptors. All of the synthesized compounds show a decrease of affinity for both 5HT(2A) and α1 receptors, as compared to trazodone, with the exception of compounds 2b,c which bear a methyl group in an α position to the aliphatic nitrogen atom N1. These compounds showed a decrease of affinity only for the α1 receptor. The stereochemical influence of the piperazine moiety of compound 2c was also evaluated. Enantiomer (S)- 2c showed the most significant differences between 5HT(2A) and α1 receptor affinity (IC50 values) and among the corresponding functional properties (pA2 values). Since (S)-2c cannot generate the metabolite 4-(3- chlorophenyl)piperazine this product was selected for further pharmacological studies.